The pharmaceutical company's net profit jumped 23.91% to Rs 246.83 crore in Q3 FY23 as compared to Rs 199.20 crore recorded in Q3 FY22.
Revenue from operations was at Rs 1,326.48 crore in Q3 FY23, up 8.34% from Rs 1,224.36 crore reported in the corresponding quarter previous year.
Profit before tax grew 25.57% year on year to Rs 334.83 crore in the quarter ended 31 December 2022.
Total expenses rose 5.65% to Rs 1,031.59 crore in Q3 FY23 over Q3 FY22. Cost of materials consumed stood at Rs 134.26 crore (up 24.23% YoY) while employee benefits expense was at Rs 135.24crore (down 4.51% YoY) during the quarter.
Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Shares of Abbott India were up 0.18% to Rs 20,897.90 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
